Clinical Trials in France / NCT03552926
Recruiting
Observational
Constitution of a Clinico-radiological Database and a Biobank for Patients With Lacunar Infarcts
NCT03552926 · tracked via the Priya Life Science France tracker
Condition(s) studied
Lacunar Strokes
Study summary
The aim of this study is to determine in patients with a recent lacunar strokes (\<15 days), the natural history of cognitive disturbances and disability.
Eligibility
Inclusion Criteria:
* Age 18 years and above
* History of recent (less than 15 days) neurological deficit related to a small subcortical infarct (evidenced by medical history or physical examination)
* Diagnosis of recent small subcortical infarct on MRI (hyperintensity on diffusion-weighted imaging showing an infarction in the territory of one perforating artery) presumably responsible for the corresponding neurological deficit
* Lesion diameter mess than 20 mm
* Ability to comply with scheduled follow-up and annual neurological evaluation
* Affiliation to the national French health insurance (sécurité sociale)
* Signature of informed consent
Exclusion Criteria:
* Prior diagnosis of dementia according to DSM IV criteria
* Prior severe disability with Rankin scale ≥ 4
* Serious concomitant systemic disorder that can compromise the follow-up study;
* Leukoencephalopathy of non-vascular origin;
* Severe psychiatric disorder;
* Inability to obtain an informed signed consent from the patient or his/her family;
* Medical contraindication or refusal to undergo cerebral magnetic resonance scanning (MRI).
Primary outcome measure(s)
- Time to the occurrence of cognitive decline — 5 years
diagnosis of mild or major neurocognitive disorder according to DSM5
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hôpital Lariboisière | Paris | France | Recruiting |
More Assistance Publique - Hôpitaux de Paris trials in France
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03552926 on ClinicalTrials.gov ↗ ← All trials in France